Delaware (State or other jurisdiction of incorporation) |
1-11397 (Commission File Number) |
33-0628076 (IRS Employer Identification No.) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.01. Completion of Acquisition or Disposition of Assets | ||||||||
Item 9.01. Financial Statements and Exhibits | ||||||||
SIGNATURES | ||||||||
EXHIBIT INDEX | ||||||||
EX-23.1 | ||||||||
EX-99.1 | ||||||||
EX-99.2 | ||||||||
EX-99.3 |
Exhibit No. | Description of Exhibit | |
23.1
|
Consent of Independent Registered Public Accounting Firm. | |
99.1
|
Audited consolidated financial statements of Dow Pharmaceutical Sciences, Inc. for the year ended December 31, 2007. | |
99.2
|
Unaudited condensed consolidated financial statements of Dow Pharmaceutical Sciences, Inc. as of September 30, 2008 and for the nine month periods ended September 30, 2008 and 2007. | |
99.3
|
Unaudited pro forma condensed consolidated financial statements. |
2
VALEANT PHARMACEUTICALS INTERNATIONAL |
||||
Date: February 27, 2009 | By: | /s/ PETER J. BLOTT | ||
Peter J. Blott | ||||
Executive Vice President and Chief Financial Officer | ||||
3
Exhibit No. | Description of Exhibit | |
23.1
|
Consent of Independent Registered Public Accounting Firm. | |
99.1
|
Audited consolidated financial statements of Dow Pharmaceutical Sciences, Inc. for the year ended December 31, 2007. | |
99.2
|
Unaudited condensed consolidated financial statements of Dow Pharmaceutical Sciences, Inc. as of September 30, 2008 and for the nine month periods ended September 30, 2008 and 2007. | |
99.3
|
Unaudited pro forma condensed consolidated financial statements. |
4